Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Recommendation of “Buy” from Analysts

Olema Pharmaceuticals, Inc. (NASDAQ:OLMAGet Free Report) has been given a consensus recommendation of “Buy” by the six ratings firms that are currently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $27.00.

Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a report on Wednesday, December 11th.

View Our Latest Stock Analysis on Olema Pharmaceuticals

Insiders Place Their Bets

In related news, CEO Sean Bohen sold 52,328 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total transaction of $490,313.36. Following the completion of the transaction, the chief executive officer now directly owns 298,836 shares in the company, valued at approximately $2,800,093.32. This trade represents a 14.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David C. Myles sold 12,452 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $9.38, for a total transaction of $116,799.76. Following the transaction, the insider now directly owns 611,947 shares of the company’s stock, valued at $5,740,062.86. This represents a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 773,797 shares of company stock worth $5,414,609. Corporate insiders own 19.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Victory Capital Management Inc. raised its holdings in Olema Pharmaceuticals by 9.9% during the third quarter. Victory Capital Management Inc. now owns 851,512 shares of the company’s stock worth $10,167,000 after acquiring an additional 76,720 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Olema Pharmaceuticals by 168.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company’s stock worth $3,949,000 after acquiring an additional 207,565 shares in the last quarter. Wellington Management Group LLP lifted its stake in Olema Pharmaceuticals by 10.8% in the third quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock valued at $11,972,000 after acquiring an additional 97,428 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Olema Pharmaceuticals in the 2nd quarter valued at about $34,753,000. Finally, Barclays PLC raised its holdings in shares of Olema Pharmaceuticals by 105.0% in the 3rd quarter. Barclays PLC now owns 94,915 shares of the company’s stock valued at $1,133,000 after purchasing an additional 48,614 shares during the period. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Stock Performance

Shares of NASDAQ:OLMA opened at $5.52 on Thursday. Olema Pharmaceuticals has a twelve month low of $4.60 and a twelve month high of $16.77. The firm has a market cap of $316.28 million, a PE ratio of -2.52 and a beta of 2.05. The business has a fifty day moving average of $8.07 and a 200-day moving average of $10.92.

Olema Pharmaceuticals Company Profile

(Get Free Report

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

Recommended Stories

Analyst Recommendations for Olema Pharmaceuticals (NASDAQ:OLMA)

Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.